32 | Humans |
17 | Plasmodium falciparum |
16 | Female |
14 | Malaria |
13 | Chloroquine |
12 | Male |
10 | Animals |
8 | Human |
7 | Treatment Outcome |
7 | Lung |
7 | Child |
7 | Antimalarials (pharmacology) |
7 | Antimalarial |
6 | Plasmodium falciparum (drug effects) |
6 | Middle Aged |
6 | Hydroxychloroquine |
6 | Chloroquine (pharmacology) |
6 | Aged |
6 | Adult |
5 | Treatment |
5 | Case study |
5 | Autophagy |
5 | Antimalarials (chemistry) |
4 | rheumatoid arthritis |
4 | ferroquine |
4 | Tomography, X-Ray Computed |
4 | Retrospective Studies |
4 | Q fever |
4 | Mutation |
4 | Infant |
4 | In vitro |
4 | Cytotoxicity |
4 | Chemotherapy |
4 | Cell Line, Tumor |
3 | malaria |
3 | chloroquine |
3 | cardiovascular disease |
3 | autophagy |
3 | Sarcoidosis |
3 | Pulmonary Surfactant-Associated Protein C (genetics) |
3 | Plasmodium |
3 | Plant origin |
3 | Parasiticide |
3 | Oxygen Inhalation Therapy |
3 | Molecular Structure |
3 | Lung Diseases, Interstitial (therapy) |
3 | Lung Diseases, Interstitial (genetics) |
3 | Hypoxia |
3 | Endocytosis |
3 | Cholesterol |
3 | Cells, Cultured |
3 | Cell Line |
3 | Biological activity |
3 | Antimalarials |
3 | Antimalarials (isolation & purification) |
3 | Adolescent |
3 | Acute |
2 | tabagisme passif |
2 | sarcoid bone lesions |
2 | resistance |
2 | primary Sjögren’s syndrome |
2 | nicotine passive exposure |
2 | mechanism of action |
2 | management |
2 | hydroxychloroquine |
2 | hair analysis |
2 | gene therapy |
2 | drug monitoring |
2 | drug candidate |
2 | calcaneus |
2 | antimalarials |
2 | antimalarial activity |
2 | analyse de cheveux |
2 | Toxicity |
2 | Time Factors |
2 | Taste (physiology) |
2 | Surfactant |
2 | Skin |
2 | Rheumatoid arthritis |
2 | Respiratory distress |
2 | Resistance |
2 | Recurrence |
2 | Receptors, G-Protein-Coupled (metabolism) |
2 | Receptors, G-Protein-Coupled (agonists) |
2 | Rats |
2 | RA, rheumatoid arthritis |
2 | Quinine |
2 | Pulmonary surfactant |
2 | Pulmonary Alveolar Proteinosis (genetics) |
2 | Prognosis |
2 | Plant Extracts (pharmacology) |
2 | Pharmacognosy |
2 | Pedigree |
2 | Pediatrics |
2 | Parasiticid |
2 | Nitrogen heterocycle |
2 | Microbial Sensitivity Tests |
2 | Mice |
2 | Methylene blue |
2 | Medicinal plant |
2 | MALARIA |
2 | Lung Neoplasms (pathology) |
2 | Lung Diseases, Interstitial (diagnostic imaging) |
2 | Hydroxychloroquine (therapeutic use) |
2 | Glucocorticoids (therapeutic use) |
2 | Gene transfer |
2 | Gene therapy |
2 | Gabon |
2 | Fatal Outcome |
2 | Edema |
2 | Drug resistance |
2 | Drug Screening Assays, Antitumor |
2 | Drug Resistance |
2 | Diagnosis |
2 | Corticosteroid |
2 | Compliance |
2 | Cell line |
2 | Cell Proliferation (drug effects) |
2 | Bronchoscopy |
2 | Bronchoalveolar Lavage Fluid (chemistry) |
2 | Biopsy |
2 | Association |
2 | Arthritis |
2 | Artemisinin |
2 | Antiplasmodial |
2 | Antineoplastic Agents, Phytogenic (pharmacology) |
2 | Antineoplastic Agents, Phytogenic (chemistry) |
2 | Antimicrobial |
2 | Amodiaquine |
2 | Alzheimer’s disease |
2 | Aged, 80 and over |
2 | Age of Onset |
2 | Adherence |
2 | AMODIAQUINE |
2 | ACR, American College of Rheumatology |
1 | β2 microglobulin |
1 | β-hematin |
1 | β-carbolines |
1 | Β-secretase modulators |
1 | |
1 | xanthones |
1 | viruses |
1 | vertebral osteomyelitis |
1 | vascular graft |
1 | urticarial vasculitis |
1 | tumour necrosis factor |
1 | tumor necrosis factor |
1 | tricyclic |
1 | treatment |
1 | traditional medicine |
1 | therapy |
1 | systemic vasculitis |
1 | systemic lupus erythematosus |
1 | syntaxin-17 |
1 | synaptosome-associated protein of 29 kDa |
1 | surveillance thérapeutique |
1 | surveillance thé |
1 | subcutaneous adipose tissue |
1 | subcellular imaging |
1 | src-Family Kinases (metabolism) |
1 | spirooxindoles |
1 | speciophylline |
1 | soins de santé primaires |
1 | silicosis |
1 | silicose |
1 | signaling |
1 | severe falciparum malaria |
1 | sensible stage |
1 | seizures |
1 | ruthenocifens |
1 | rodent Plasmodium |
1 | rituximab |
1 | reversal agent |
1 | retinal toxicity |
1 | replication |
1 | receptor-mediated endocytosis |
1 | reactive species |
1 | rapeutique |
1 | rapamycin |
1 | quinoline resistance |
1 | quinidine like effect |
1 | pédiatrie |
1 | pulmonary edema |
1 | primary immune deficiency |
1 | primary health care |
1 | polyplexes |
1 | polymyositis |
1 | podocyte |
1 | pneumoconiosis |
1 | pneumoconiose |
1 | plasmid |
1 | piperazine |
1 | picornavirus |
1 | phé |
1 | phytotherapy |
1 | phenobarbital |
1 | phenanthroline |
1 | pharmacology |
1 | pediatrics |
1 | paludisme grave |
1 | pSS, primary Sjögren’s syndrome |
1 | pLK, poly-l-lysine. |
1 | pH-sensitive |
1 | obesity |
1 | non hodgkin lymphoma |
1 | nobarbital |
1 | neurotrophins |
1 | neurodegeneration |
1 | nanoparticles |
1 | myocarditis |
1 | mortalité |
1 | mortality |
1 | morbidité |
1 | morbidity |
1 | monoclonal antibody |
1 | methylene blue |
1 | metallodrug activity |
1 | mature schizonts |
1 | magnetic resonance imaging |
1 | mAMSA, 4′-(9-acridinylamino)-methanesulfon-m-anisidide |
1 | lysosome |
1 | lung |
1 | luciferase |
1 | liposome |
1 | lipids |
1 | kidney |
1 | intracellular traffic |
1 | intoxication |
1 | interleukin-6 |
1 | infected abdominal aortic aneurysm |
1 | increasing dose |
1 | in vitro |
1 | immune response |
1 | hydroxychloroquine blood concentration |
1 | human t-lymphotropic virus 1 |
1 | high-mobility group proteins |
1 | hemicatenane |
1 | heart |
1 | haem. |
1 | granulomatous disease |
1 | glycoplexes |
1 | glycoconjugates |
1 | glutathione |
1 | glomerulus |
1 | free merozoites |
1 | fractionation |
1 | fibrosis |
1 | ferrocifens |
1 | extracellular matrix |
1 | exchange transfusion |
1 | enterovirus |
1 | enterovirus A71 |
1 | endocytosis |
1 | electropermeabilisation |
1 | early rheumatoid arthritis |
1 | drugs of abuse |
1 | drug-binding proteins |
1 | drug uptake |
1 | drug resistance |
1 | drug interactions |
1 | drug delivery |
1 | drogues |
1 | doxycycline |
1 | dmards (synthetic) |
1 | disease activity |
1 | dermatomyositis |
1 | dendritic cells |
1 | decision tree |
1 | deca-2E 6Z 8E-trienoic acid isobutylamide |
1 | cytotoxicity |
1 | cutaneous lupus erythematosus |
1 | connectivite |
1 | connective tissue diseases |
1 | colorectal cancer |
1 | collagen |
1 | chloroquine gels |
1 | child |
1 | chemosensitizer |
1 | cell culture |
1 | bronchoalveolar lavage fluid |
1 | bleomycin |
1 | bioorganometallics |
1 | bioorganometallic chemistry |
1 | autolysosome |
1 | autoimmunity |
1 | asthma |
1 | arthritis |
1 | apoptosis |
1 | antitrypanosomal activity |
1 | antirheumatic agents |
1 | antiplasmodial activity |
1 | antiparasitic agents |
1 | antimalarial drug |
1 | antimalarial drug resistance |
1 | antileishmanial activity |
1 | antidepressant |
1 | antibody deficiency |
1 | anti-SSA/SSB |
1 | amyloid precursor protein |
1 | alveolitis, extrinsic allergic |
1 | alternative DNA conformations |
1 | alkylamides |
1 | adalimumab |
1 | Young adult |
1 | Xanthones (pharmacology) |
1 | Xanthones (chemistry) |
1 | XMEA |
1 | Withania frutescens |
1 | Whipple Disease (epidemiology) |
1 | Whipple Disease (drug therapy) |
1 | Whipple Disease (cerebrospinal fluid) |
1 | Wall |
1 | Virus Replication |
1 | Viral entry |
1 | Viral Nonstructural Proteins |
1 | Vietnam |
1 | Vasolin containing protein |
1 | Vascular infection |
1 | VCP |
1 | Uroporphyrins |
1 | Upper limb |
1 | Ubiquitin (metabolism) |
1 | Two-Hybrid System Techniques |
1 | Tumor |
1 | Tumor cell susceptibility |
1 | Tsc1 |
1 | Tropheryma whipplei |
1 | Tropheryma (pathogenicity) |
1 | Tropheryma (drug effects) |
1 | Triterpenes (pharmacology) |
1 | Triterpenes (isolation & purification) |
1 | Triterpenes (chemistry) |
1 | Triglycerides |
1 | Trichloromethyl goup |
1 | Treatment efficiency |
1 | Translation elongation |
1 | Traditional remedy |
1 | Traditional medicine |
1 | Tracheostomy |
1 | Toxins |
1 | Tomography, X-Ray Computed (methods) |
1 | Thyroid Nuclear Factor 1 (genetics) |
1 | Therapeutic drug monitoring |
1 | Therapeutic agent |
1 | Th17-mediated disease |
1 | Tetralone |
1 | Terpenes (pharmacology) |
1 | Terpenes (isolation & purification) |
1 | Terpenes (chemistry) |
1 | Temperature |
1 | Taste |
1 | TRIS |
1 | TNF |
1 | TNF, tumour necrosis factor |
1 | TGF-BMP: transforming growth factor-bone morphogenic protein ARTICLE HISTORY KEYWORDS ATG7 |
1 | TB, tuberculosis |
1 | T-Lymphocytes, Cytotoxic (immunology) |
1 | Systemic |
1 | Systemic sclerosis |
1 | Systemic lupus erythematosus |
1 | Synovitis |
1 | Symptomatology |
1 | Survival |
1 | Suicide |
1 | Strychnobrasiline |
1 | Strychnine (pharmacology) |
1 | Structure-Activity Relationship |
1 | Structure activity relation |
1 | Structural analysis |
1 | Streric block oligonucleotide analogues |
1 | Stomatocytogenesis |
1 | Stereoisomerism |
1 | Stem |
1 | Status Epilepticus/diagnostic imaging/drug therapy/*etiology |
1 | Spondyloarthritis |
1 | Splice correction and cancer |
1 | Sjögren's syndrome |
1 | Sjögren syndrome |
1 | Six membered ring |
1 | Signal transducer and activator of transcription 3 |
1 | Signal Transduction |
1 | Signal Transduction (physiology) |
1 | Signal Transduction (drug effects) |
1 | Siblings |
1 | Severity score |
1 | Severe Malaria |
1 | Sequestosome-1 Protein |
1 | Sepiolite |
1 | Senegal |
1 | Selectivity |
1 | Selectivity index |
1 | Secondary prevention |
1 | Screening |
1 | Scleroderma |
1 | Scintigraphy |
1 | ScAT: subcutaneous adipose tissue |
1 | Sarcoidosis (genetics) |
1 | Sarcoidosis (drug therapy) |
1 | Saponin B |
1 | SYBR green |
1 | SULFADOXINE-PYRIMETHAMINE |
1 | STAT3 Transcription Factor (metabolism) |
1 | SSZ, sulfasalazine |
1 | SSA/SSB, Sjögren’s syndrome antigen A or B |
1 | SOUTHEAST-ASIA |
1 | SNARE |
1 | SLEDAI, SLE disease activity index |
1 | SLE, systemic lupus erythematosus |
1 | SJC, swollen joint count |
1 | SIR, standardised incidence ratio |
1 | SEER, Surveillance, Epidemiology, and End Results |
1 | SDS, sodium dodecyl sulfate |
1 | SAE, serious adverse event |
1 | Roscovitine |
1 | Rituximab |
1 | Risk Factors |
1 | Rheumatoid |
1 | Rheedia acuminata |
1 | Respiratory tract |
1 | Respiratory disease |
1 | Respiratory Tract Diseases (metabolism) |
1 | Respiratory System (metabolism) |
1 | Respiratory Function Tests (methods) |
1 | Respiratory Distress Syndrome, Newborn (pathology) |
1 | Respiratory Distress Syndrome, Newborn (genetics) |
1 | Respiratory Distress Syndrome, Newborn (etiology) |
1 | Respiratory Distress Syndrome, Newborn (complications) |
1 | Respiratory Distress Syndrome, Adult (therapy) |
1 | Respiratory Distress Syndrome, Adult (genetics) |
1 | Respiratory Distress Syndrome, Adult (etiology) |
1 | Respiration, Artificial |
1 | Research Design |
1 | Regression |
1 | Redux |
1 | Reduced glutathione- O-phthalaldehyde |
1 | Recommendations |
1 | Receptors, G-Protein-Coupled (physiology) |
1 | Receptors, G-Protein-Coupled (drug effects) |
1 | Receptors, Cell Surface (physiology) |
1 | Receptors, Cell Surface (metabolism) |
1 | Receptors, Cell Surface (drug effects) |
1 | Receptors, Cell Surface (agonists) |
1 | Rat |
1 | Raqaypampeños |
1 | Raptor |
1 | Radiography |
1 | Radiography, Thoracic |
1 | Radical scavenging |
1 | Quinoline derivatives |
1 | Quechua |
1 | Qc-SNARE Proteins |
1 | Qb-SNARE Proteins |
1 | Qa-SNARE Proteins |
1 | Q Fever/complications/*diagnosis/drug therapy |
1 | Périnatalité |
1 | Pyrrolo[1 |
1 | Pyrostria major |
1 | Pyrazoles (therapeutic use) |
1 | Pyomyositis |
1 | Purvalanol |
1 | Pulmonary hypertension |
1 | Pulmonary Surfactants (metabolism) |
1 | Pulmonary Surfactant-Associated Protein C (analysis) |
1 | Pulmonary Surfactant-Associated Protein B (genetics) |
1 | Pulmonary Surfactant-Associated Protein B (deficiency) |
1 | Pulmonary Fibrosis (therapy) |
1 | Pulmonary Fibrosis (diagnosis) |
1 | Pulmonary Edema (pathology) |
1 | Pulmonary Edema (complications) |
1 | Pulmonary Alveolar Proteinosis (diagnosis) |
1 | Pulmonary Alveolar Proteinosis (complications) |
1 | Public health |
1 | Psidium acutangulum |
1 | Pseudomonas Infections (etiology) |
1 | Pseudomonas Infections (diagnostic imaging) |
1 | Protein Interaction Mapping |
1 | Protein C |
1 | Protein Binding |
1 | Proteasome |
1 | Proteasome Endopeptidase Complex (metabolism) |
1 | Pro-drug |
1 | Primary antiphospholipid syndrome |
1 | Primary Sjögren's syndrome |
1 | Porphyria Cutanea Tarda |
1 | Porifera (chemistry) |
1 | Polymyalgia Rheumatica |
1 | Polylysine |
1 | Polycythemia Vera (genetics) |
1 | Polycythemia Vera (drug therapy) |
1 | Poisoning |
1 | Pneumopathy |
1 | Pneumonia, Pneumocystis (etiology) |
1 | Pneumonia, Pneumocystis (diagnostic imaging) |
1 | Pneumonia, Bacterial (etiology) |
1 | Pneumonia, Bacterial (diagnostic imaging) |
1 | Pneumology |
1 | Platinum |
1 | Plasmodium falciparum (metabolism) |
1 | Plasmodium berghei |
1 | Plants, Medicinal (chemistry) |